PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB
CNAO 44 2021C
Phase 2 small_molecule active
Quick answer
PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB for Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC) is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active